Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -84.78% is 59% below its 5-year average of -53.36%, near the low end of its 5-year range (-85.77%–-22.37%).
As of the fiscal period ended Sunday, May 31, 2026. 37.92% below its 12-month average of -61.47%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-05-31): -84.78%.
RETURN ON EQUITY (ROE)
-84.78%
RETURN ON EQUITY (ROE) AVG TTM
-61.47%
RETURN ON EQUITY (ROE) AVG 3Y
-58.51%
RETURN ON EQUITY (ROE) AVG 5Y
-53.36%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-37.92%
CURRENT VS 3Y AVG
-44.90%
CURRENT VS 5Y AVG
-58.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-101.81%
vs the sector median at left
Nurix Therapeutics, Inc.
Market Cap
$2.34B
Return on Equity (ROE)
-84.78%
TTM Avg
-61.47%
3Y Avg
-58.51%
5Y Avg
-53.36%
Market Cap
$2.35B
Return on Equity (ROE)
71.04%
TTM Avg
-161.38%
3Y Avg
-133.53%
5Y Avg
-111.86%
Market Cap
$2.33B
Return on Equity (ROE)
15.63%
TTM Avg
16.66%
3Y Avg
16.66%
5Y Avg
13.72%
Market Cap
$2.36B
Return on Equity (ROE)
41.39%
TTM Avg
43.71%
3Y Avg
5.79%
5Y Avg
-18.90%
Market Cap
$2.37B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
9.38%
5Y Avg
9.38%
Market Cap
$2.39B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$2.29B
Return on Equity (ROE)
18.14%
TTM Avg
20.16%
3Y Avg
28.24%
5Y Avg
15.58%
Market Cap
$2.40B
Return on Equity (ROE)
-4.88%
TTM Avg
-20.16%
3Y Avg
-52.49%
5Y Avg
-49.61%
Market Cap
$2.42B
Return on Equity (ROE)
-38.17%
TTM Avg
-26.66%
3Y Avg
-25.50%
5Y Avg
23.47%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | $2.34B | -84.78% | -61.47% | -58.51% | -53.36% |
| Liquidia Corporation (LQDA)vs › | $2.35B | 71.04% | -161.38% | -133.53% | -111.86% |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 15.63% | 16.66% | 16.66% | 13.72% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 41.39% | 43.71% | 5.79% | -18.90% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.37B | N/A | 9.38% | 9.38% | 9.38% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.39B | -56.71% | -50.91% | -55.48% | -35.68% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 18.14% | 20.16% | 28.24% | 15.58% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -4.88% | -20.16% | -52.49% | -49.61% |
| Disc Medicine, Inc. (IRON)vs › | $2.42B | -38.17% | -26.66% | -25.50% | 23.47% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.24B | -37.82% | -53.05% | -23.57% | 8.38% |
ROE
-84.8%
ROA
-63.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-05-31 | -84.78% |
| 2026-02-28 | -61.40% |
| 2025-11-30 | -49.09% |
| 2025-08-31 | -65.76% |
| 2025-05-31 | -46.32% |
| 2025-02-28 | -43.33% |
| 2024-11-30 | -36.73% |
| 2024-08-31 | -46.96% |
| 2024-05-31 | -44.51% |
| 2024-02-29 | -85.77% |
| 2023-11-30 | -71.80% |
| 2023-08-31 | -63.60% |
| 2023-05-31 | -60.57% |
| 2023-02-28 | -65.16% |
| 2022-11-30 | -59.39% |
| 2022-08-31 | -50.02% |
| 2022-05-31 | -57.91% |
| 2022-02-28 | -44.28% |
| 2021-11-30 | -34.24% |
| 2021-08-31 | -26.49% |
| 2021-05-31 | -22.37% |
| 2021-02-28 | -20.41% |
| 2020-11-30 | -14.90% |
| 2020-08-31 | -11.98% |
| 2020-05-31 | -19.47% |
